{
    "clinical_study": {
        "@rank": "65504", 
        "arm_group": {
            "arm_group_label": "Targeted Biopsy", 
            "arm_group_type": "Other", 
            "description": "Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment.  Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment.  All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy.  As a result the study includes a single arm with direct comparison of biopsy techniques."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective single center trial to examine the rates of cancer diagnosis when\n      using computerized software to target suspicious lesions within the prostate identified on\n      mpMRI.  The primary evaluation involves comparing the rate of cancer diagnosis when using\n      software-based MRI-Ultrasound image fusion guided biopsy  to sample mpMRI findings to the\n      use of visual guided biopsy (cognitive or mental targeting) of the same target.  The\n      hypothesis being tested is that fusion guided biopsy will increase detection prostate cancer\n      within mpMRI findings as compared to visual guided biopsy of these areas"
        }, 
        "brief_title": "Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  No previous diagnosis of adenocarcinoma of the prostate\n\n          -  No contraindication to prostate biopsy (e.g. coagulopathy, medical condition\n             prohibiting abstinence from anti-platelet or anticoagulation therapies, anatomical\n             considerations, anatomical considerations)\n\n          -  Active urinary tract infection\n\n        Exclusion Criteria:\n\n          -  Prior pelvic radiotherapy\n\n          -  Prior androgen deprivation therapy\n\n          -  Evidence urinary tract infection or significant urinary retention\n\n          -  Prostate instrumentation (e.g. prostate biopsy, transurethral prostate procedure)\n             within 2 months prior to mpMRI.\n\n          -  Contraindication to MRI (severe claustrophobia, indwelling metallic objects\n             incompatible with MRI, pacemaker)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964638", 
            "org_study_id": "S12-01613"
        }, 
        "intervention": {
            "arm_group_label": "Targeted Biopsy", 
            "intervention_name": "Targeted Biopsy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Prostate Cancer", 
            "Prostate Biopsy", 
            "Targeted Biopsy"
        ], 
        "lastchanged_date": "October 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU Smilow Prostate Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparative Analysis of Software-based MRI-Ultrasound Image Fusion Against Cognitive Targeting of Multi-Parametric MRI Findings With Prostate Biopsy", 
        "overall_official": {
            "affiliation": "Co-Director, Smilow Comprehensive Prostate Cancer Center", 
            "last_name": "Samr S Taneja, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is the evaluation of the rates of prostate cancer diagnosis using software based MRI-TRUS imaging fusion targeting of mpMRI lesions as compared to cognitive co-registration and targeting of mpMRI lesions.", 
            "measure": "Evaluation of rates of prostate cancer diagnosis", 
            "safety_issue": "No", 
            "time_frame": "One week after biopsy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964638"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York University School of Medicine", 
            "investigator_full_name": "Samir Taneja, MD", 
            "investigator_title": "Co-Director, Smilow Comprehensive Prostate Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The secondary endpoint of the study is the evaluation of the rate of cancer diagnosis using targeted biopsy (software or cognitive targeting) as compared to standard of care prostate biopsy.", 
            "measure": "Evaluation of Rate of cancer diagnosis using targeted biopsy", 
            "safety_issue": "No", 
            "time_frame": "One week after biopsy"
        }, 
        "source": "New York University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}